Ekso Bionics Holdings, Inc.

Introduction

This page provides a comprehensive analysis of the known insider trading history of Theodore T Wang. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Theodore T Wang has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:BLPH / Bellerophon Therapeutics, Inc. 10% Owner 0
US:MRDB / MariaDB plc Director 2,659,568
US:POND / Angel Pond Holdings Corp - Class A 10% Owner 6,637,870
US:EKSO / Ekso Bionics Holdings, Inc. Director 29,828
US:TCON / TRACON Pharmaceuticals, Inc. 10% Owner 76,048
US:VRAY / ViewRay Inc. Director 34,117
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Theodore T Wang. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases EKSO / Ekso Bionics Holdings, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in EKSO / Ekso Bionics Holdings, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

EKSO / Ekso Bionics Holdings, Inc. Insider Trades
Insider Sales EKSO / Ekso Bionics Holdings, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in EKSO / Ekso Bionics Holdings, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

EKSO / Ekso Bionics Holdings, Inc. Insider Trades
Insider Purchases VRAYQ / ViewRay, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in EKSO / Ekso Bionics Holdings, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VRAYQ / ViewRay, Inc. Insider Trades
Insider Sales VRAYQ / ViewRay, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in EKSO / Ekso Bionics Holdings, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VRAYQ / ViewRay, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Theodore T Wang as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2023-10-16 2023-10-13 4 BLPH Bellerophon Therapeutics, Inc.
Common Stock
S - Sale -1,076,841 0 -100.00 0.10 -111,776
2023-06-30 2023-06-29 4 MRDB MariaDB plc
Ordinary Shares
A - Award 182,291 2,659,568 7.36
2023-06-07 2023-06-07 4 BLPH Bellerophon Therapeutics, Inc.
Common Stock
S - Sale -134,421 1,076,841 -11.10 0.83 -111,569 893,778
2023-05-19 2023-05-18 4 BLPH Bellerophon Therapeutics, Inc.
Common Stock
S - Sale -560,000 1,211,262 -31.62 9.46 -5,297,600 11,458,539
2023-05-15 2023-05-11 4 MRDB MariaDB plc
Ordinary Shares
A - Award 48,342 2,477,277 1.99
2022-12-19 2022-12-16 4 MRDB MariaDB plc
Ordinary Shares
A - Award 2,428,935 2,428,935
2022-02-02 2022-01-28 4 POND Angel Pond Holdings Corp
Class B Ordinary Shares
J - Other 0 6,637,870 0.00
2022-01-04 2021-12-31 4 BLPH Bellerophon Therapeutics, Inc.
Stock Options (right to buy)
A - Award 21,828 35,634 158.11 3.10 67,667 110,465
2021-07-07 2021-07-02 4 POND Angel Pond Holdings Corp
Class B Ordinary Shares
J - Other -549,630 6,637,870 -7.65
2021-06-08 2021-06-07 4 BLPH Bellerophon Therapeutics, Inc.
Common Stock
A - Award 8,189 1,771,262 0.46 4.00 32,756 7,085,048
2021-05-20 2021-05-18 4 POND Angel Pond Holdings Corp
Class B Ordinary Shares
J - Other -1,437,500 7,187,500 -16.67
2021-04-26 2021-04-26 4 BLPH Bellerophon Therapeutics, Inc.
Warrants (Right to buy)
A - Award 304,286 685,236 79.88
2021-04-26 2021-04-26 4 BLPH Bellerophon Therapeutics, Inc.
Warrants (Right to buy)
A - Award 380,950 380,950
2021-04-26 2021-04-26 4 BLPH Bellerophon Therapeutics, Inc.
Common Stock
A - Award 609,231 1,763,077 52.80 4.00 2,436,924 7,052,308
2020-11-12 2020-11-10 4 EKSO EKSO BIONICS HOLDINGS, INC.
Common Stock
J - Other -744,572 29,828 -96.15
2020-09-14 2020-09-10 4 BLPH Bellerophon Therapeutics, Inc.
Stock Option (right to buy)
A - Award 6,509 13,806 89.20 10.12 65,871 139,717
2020-07-27 2020-07-23 4 EKSO EKSO BIONICS HOLDINGS, INC.
Common Stock
A - Award 7,383 9,958 286.72
2020-06-09 2020-06-08 4 BLPH Bellerophon Therapeutics, Inc.
Common Stock
P - Purchase 2,600 60,913 4.46 12.87 33,454 783,768
2020-06-09 2020-06-05 4 BLPH Bellerophon Therapeutics, Inc.
Common Stock
P - Purchase 4,986 58,313 9.35 12.72 63,442 741,975
2020-05-22 2020-05-21 4 BLPH Bellerophon Therapeutics, Inc.
Common Stock
A - Award 1,153,846 1,153,846 13.00 14,999,998 14,999,998
2020-04-20 2020-04-17 4 BLPH Bellerophon Therapeutics, Inc.
Common Stock
J - Other -553,250 0 -100.00
2020-03-04 2020-03-02 4 EKSO EKSO BIONICS HOLDINGS, INC.
Common Stock
J - Other -8,918,898 11,616,000 -43.43
2020-01-21 2020-01-16 4 EKSO EKSO BIONICS HOLDINGS, INC.
Stock Option (right to buy)
A - Award 136,496 136,496
2020-01-21 2020-01-16 4 EKSO EKSO BIONICS HOLDINGS, INC.
Common Stock
A - Award 19,445 38,624 101.39 0.45 8,750 17,381
2019-12-11 2019-12-09 4 TCON Tracon Pharmaceuticals, Inc.
Common Stock
S - Sale -340,134 76,048 -81.73 2.92 -993,191 222,060
2019-12-11 2019-12-05 4 TCON Tracon Pharmaceuticals, Inc.
Common Stock
S - Sale -43,996 416,182 -9.56 3.05 -134,188 1,269,355
2019-11-25 2019-11-25 4 BLPH Bellerophon Therapeutics, Inc.
Common Stock
P - Purchase 7,193 592,922 1.23 0.39 2,774 228,631
2019-11-25 2019-11-22 4 BLPH Bellerophon Therapeutics, Inc.
Common Stock
P - Purchase 1,050 585,729 0.18 0.37 394 219,531
2019-11-25 2019-11-21 4 BLPH Bellerophon Therapeutics, Inc.
Common Stock
P - Purchase 200 584,679 0.03 0.37 74 216,331
2019-09-30 2019-09-26 4 BLPH Bellerophon Therapeutics, Inc.
Stock Option (right to buy)
A - Award 46,266 109,482 73.19
2019-06-14 2019-06-12 4 BLPH Bellerophon Therapeutics, Inc.
Common Stock
P - Purchase 50,000 584,479 9.35 0.64 31,905 372,956
2019-05-24 2019-05-22 4 BLPH Bellerophon Therapeutics, Inc.
Common Stock
P - Purchase 27,500 534,479 5.42 0.60 16,533 321,329
2019-05-22 2019-05-21 4 BLPH Bellerophon Therapeutics, Inc.
Common Stock
P - Purchase 43,280 506,979 9.33 0.61 26,371 308,902
2019-01-25 2019-01-25 4 BLPH Bellerophon Therapeutics, Inc.
Common Stock
P - Purchase 450,000 463,699 3,284.91 0.70 315,000 324,589
2019-01-03 2019-01-02 4 VRAY ViewRay, Inc.
Common Stock
A - Award 18,668 34,117 120.84
2019-01-03 2019-01-02 4 VRAY ViewRay, Inc.
Common Stock
A - Award 7,305 15,449 89.70 6.16 44,999 95,166
2018-12-26 2018-12-21 4 VRAY ViewRay, Inc.
Stock Option (right to buy)
A - Award 19,116 19,116
2018-12-03 2018-11-29 4 TCON Tracon Pharmaceuticals, Inc.
Common Stock
S - Sale 4,326 4,601,768 0.09 1.21 5,234 5,568,139
2018-12-03 2018-11-29 4 TCON Tracon Pharmaceuticals, Inc.
Common Stock
P - Purchase 4,326 4,606,094 0.09 1.13 4,888 5,204,886
2018-12-03 2018-11-29 4/A TCON Tracon Pharmaceuticals, Inc.
Common Stock
S - Sale -4,326 4,601,768 -0.09 1.21 -5,234 5,568,139
2018-12-03 2018-11-29 4/A TCON Tracon Pharmaceuticals, Inc.
Common Stock
P - Purchase 4,326 4,606,094 0.09 1.13 4,888 5,204,886
2018-08-07 2018-08-03 4 EKSO EKSO BIONICS HOLDINGS, INC.
Employee Stock Option (right to buy)
A - Award 41,000 41,000
2018-08-07 2018-08-03 4 EKSO EKSO BIONICS HOLDINGS, INC.
Common Stock
A - Award 19,179 19,179 1.79 34,330 34,330
2018-08-03 2018-08-02 4 VRAY ViewRay, Inc.
Common Stock
A - Award 1,928 8,144 31.02 8.18 15,771 66,618
2018-07-05 2018-07-02 4 VRAY ViewRay, Inc.
Common Stock
A - Award 2,808 6,216 82.39 7.12 19,993 44,258
2018-06-25 2018-06-21 4 BLPH Bellerophon Therapeutics, Inc.
Common Stock
A - Award 13,699 13,699
2018-06-13 2018-06-13 4 TCON Tracon Pharmaceuticals, Inc.
Director Stock Option (Right to Buy)
A - Award 15,000 15,000
2018-06-07 2018-06-05 4 BLPH Bellerophon Therapeutics, Inc.
Stock Option (right to buy)
A - Award 38,216 63,216 152.86 2.27 86,750 143,500
2018-04-26 2017-11-15 4 VRAY ViewRay, Inc.
Stock Option (right to buy)
A - Award 18,459 18,459
2018-04-26 2017-11-15 4 VRAY ViewRay, Inc.
Common Stock
A - Award 3,408 3,408
2018-04-13 3 BLPH Bellerophon Therapeutics, Inc.
Common Stock
16,597,510
2018-04-13 3 BLPH Bellerophon Therapeutics, Inc.
Common Stock
16,597,510
2018-04-13 3 BLPH Bellerophon Therapeutics, Inc.
Common Stock
16,597,510
2018-04-13 3 BLPH Bellerophon Therapeutics, Inc.
Common Stock
16,597,510
2018-04-13 3 BLPH Bellerophon Therapeutics, Inc.
Common Stock
16,597,510
2018-04-13 3 BLPH Bellerophon Therapeutics, Inc.
Common Stock
16,597,510
2018-04-13 3 BLPH Bellerophon Therapeutics, Inc.
Common Stock
16,597,510
2018-04-09 2018-04-06 4 TCON Tracon Pharmaceuticals, Inc.
Director Stock Option (Right to Buy)
A - Award 25,000 25,000
2018-04-05 3 TCON Tracon Pharmaceuticals, Inc.
Common Stock
9,203,536
2018-04-05 3 TCON Tracon Pharmaceuticals, Inc.
Common Stock
9,203,536
2018-04-05 3 TCON Tracon Pharmaceuticals, Inc.
Common Stock
9,203,536
2018-04-05 3 TCON Tracon Pharmaceuticals, Inc.
Common Stock
9,203,536
2018-04-05 3 TCON Tracon Pharmaceuticals, Inc.
Common Stock
9,203,536
2018-04-05 3 TCON Tracon Pharmaceuticals, Inc.
Common Stock
9,203,536
2018-04-05 3 TCON Tracon Pharmaceuticals, Inc.
Common Stock
9,203,536
2018-04-05 3 TCON Tracon Pharmaceuticals, Inc.
Common Stock
9,203,536
2017-12-14 2017-12-12 4 BLPH Bellerophon Therapeutics, Inc.
Stock Option (right to buy)
A - Award 25,000 25,000
2017-12-04 3 BLPH Bellerophon Therapeutics, Inc.
Common Stock
16,597,510
2017-12-04 3 BLPH Bellerophon Therapeutics, Inc.
Common Stock
16,597,510
2017-09-25 3 EKSO EKSO BIONICS HOLDINGS, INC.
Common Stock
41,069,796
2017-09-25 3 EKSO EKSO BIONICS HOLDINGS, INC.
Common Stock
41,069,796
2017-09-25 3 EKSO EKSO BIONICS HOLDINGS, INC.
Common Stock
41,069,796
2017-09-25 3 EKSO EKSO BIONICS HOLDINGS, INC.
Common Stock
41,069,796
2017-09-25 3 EKSO EKSO BIONICS HOLDINGS, INC.
Common Stock
41,069,796
2017-09-25 3 EKSO EKSO BIONICS HOLDINGS, INC.
Common Stock
41,069,796
2017-01-25 2017-01-24 4 VRAY ViewRay, Inc.
Stock Option (right to buy)
A - Award 19,556 19,556
2017-01-25 3 VRAY ViewRay, Inc.
Common Stock
13,685,950
2017-01-25 3 VRAY ViewRay, Inc.
Common Stock
13,685,950
2017-01-25 3 VRAY ViewRay, Inc.
Common Stock
13,685,950
2017-01-25 3 VRAY ViewRay, Inc.
Common Stock
13,685,950
2017-01-25 3 VRAY ViewRay, Inc.
Common Stock
13,685,950
2017-01-25 3 VRAY ViewRay, Inc.
Common Stock
13,685,950
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)